LARGE ARTERIES such as the carotid, coronary, and renal arteries are traditionally thought of as passive conduits whose principal function is to conduct and distribute cardiac output to various tissues.1 Conduit arteries represent a low resistance system that is not thought to be involved with blood flow regulation. Most of the research in hypertension has focused on the small arteries and resistance arterioles.2 However, our recent knowledge of the pathology and physiology of the large arteries suggests that these vessels may play an important role in the pathophysiology of hypertensive vascular disease.3 For example, large arteries have an important buffering function to phasic changes in pressure. ' The distensibility of these vessels affects the impedance to ventricular ejection, which is important in determining end-systolic ventricular wall stress, an important factor in the pathophysiology of cardiac hypertrophy and failure.1-4 Furthermore, large vessels are prone to develop arteriosclerosis, which is the major cause of cardiovascular complications. prostacyclin, nitroprusside, atrial natriuretic factor, etc.5 6 Recent reports of the exsistence of a local reninangiotensin system in blood vessel walls, especially in large arteries, have raised the possibility that vascular function may be regulated by local production of angiotensin II independent of the circulating levels.7 10 Indeed, recent experimental and clinical studies have demonstrated that blockade of angiotensin II production by angiotensin converting-enzyme inhibitors increased the compliance of these large arteries.11' 12 Taken together, these data raise new and important questions in the control of the functions of the large arteries.
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The purpose of this brief review is to examine the role of large arteries in hypertension and to elucidate the contribution of the vascular renin-angiotensin system to the pathophysiology and therapy of hypertension.
Importance of large arteries in hypertension. It is well recognized that the complications associated with hypertension are frequently the result of arteriosclerotic vascular disease. Large vessels are particularly prone to injury because of the continued exposure to high pulsatile pressure and shear stress. ' The thickness of these vessels also increases the potential of increased lipoprotein deposition.13' 14 Endothelial dysfunction or denudation that results from hemodynamic injury and/or metabolic imbalances can elicit a sequence of responses in the blood vessel wall that eventually lead to formation of the arteriosclerotic plaque.15 Thus, the adaptive properties of large artery to changes in pressure and shear stress may be important deterrents to vascular injury. [1] [2] [3] [4] In other words, the viscoelastic and compliant properties of these vessels provide a buffer to abrupt increases in pressure. Factors [27] [28] [29] In the presence of congestive heart failure, afterload reduction has become an established therapeutic modality. In this condition, activation of angiotensin and norepinephrine can increase afterload, resulting in increased wall stress and aggravation of heart failure,30' 31 Angiotensin converting-enzyme inhibitors are particularly efficacious in the treatment of this disorder.32 '3 Concepts and determinants of arterial hemodynamics.
Studies of arterial hemodynamics in humans are usually based on invasive recordings of pressure and flow in the aorta. Thus, the impedance spectrum of large PERSPECTIVE arteries may be evaluated, enabling the simultaneous investigation of the resistance, capacitance, and inertia of the arterial system. 35 The conduit function of the large artery may be studied from the determination of arterial diameter and blood flow velocity. Assuming a cylindrical model of the artery, the arterial cross-sectional area can be estimated from the measured diameter. Blood flow can be calculated as the product of the cross-sectional area and blood flow velocity. Resistance is calculated as the ratio between mean arterial pressure and brachial blood flow.
Thus, the pulsed Doppler system provides important information about the degree of arterial dilation5: (1) dilation of small arteries is indirectly inferred from the calculation of vascular resistance, and (2) dilation of large arteries is evaluated directly from the large artery diameter measurement.
The buffering function oflarge arteries may be investigated from the determination of arterial compliance, which is the slope of the pressure-volume relationship within the artery, i.e., the ratio between the change in volume (dV) divided by the change in pressure (dP). [1] [2] [3] [4] Propagative and nonpropagative models of the forearm circulation have been described for the determination of compliance. The 63 observed that aortic, mesenteric, and renal ACE activities were increasing during chronic two-kidney, one-clip renovascular hypertension in the rat, despite normal plasma renin activity. Indeed, angiotensin II generation appears to be accelerated in the aortic wall in these animals and the administration of convertingenzyme inhibitors/angiotensin II antagonists ameliorates the elevation in blood pressure.62 63 Vascular angiotensin II may influence large artery function through the direct activation of angiotensin II receptors in the smooth muscle cells. Alternatively, local angiotensin may influence blood vessel contractility by facilitating catecholamine release from noradrenergic nerve endings.
Evidence for angiotensin hyperreactivity in large arteries in human essential hypertension has been provided by clinical studies. It has been observed that converting-enzyme inhibitors (captopril and enalapril) cause a significant increase in arterial diameter in both the brachial37' 64, 65 and carotid arteries.17 With longterm enalapril therapy (up to 6 months), the diameter enhancement is maintained.29 In contrast, convertingenzyme inhibitors do not influence arterial diameter, blood flow, or indexes of arterial stiffness (as measured in the brachial artery) of normal healthy volunteers.12
This observation supports a contribution of vascular angiotensin rather than its serum counterpart in mediating the altered arterial compliance in hypertension since in both of these cited studies serum ACE activities were inhibited up to 95%.
In another study involving normal volunteers, high doses of the converting-enzyme inhibitor Perindopril were required to produce significant increases in arterial diameter and blood flow.62 In contrast, in hypertensive subjects, conventional doses of the convertingenzyme inhibitor influenced arterial hemodynamics. These findings were obtained in the presence of significant blood pressure reductions, suggesting that the mechanical effects of blood pressure were offset by the dilating effects of converting-enzyme inhibitor."
Taken together, these results suggest that hypertensive subjects may have enhanced production of or sensitivity to local angiotensin.
Effects of converting-enzyme inhibitors and other antihypertensive agents on the conduit and buffering function of large arteries. Angiotensin converting-enzyme inhibitors (captopril, enalapril, and ramipril) cause arterial vasodilatation and induce an increase in flow velocity in the large artery. As mentioned above, these agents also increase cross-sectional area of the large arteries, which may play a role in the increase of blood flow. The quantitative contribution of the increase in arterial caliber to the flow increases in the carotid, cerebral, coronary, and renal circulations is unclear. In conditions associated with intense angiotensin Il-mediated vasoconstriction of the renal arteries, such as hepatorenal syndrome and congestive heart failure, convertingenzyme inhibition and angiotensin LI antagonism, in addition to their effect on the arterioles,31' 66 have been shown to increase renal blood flow based on relaxation of the large and medium-sized arteries. Under conditions of large artery stenosis, an increase in large artery caliber may be an important factor in maintaining flow during converting-enzyme inhibition since the arterioles are maximally vasodilated. As mentioned, it has been suggested that the dilating effect of captopril on the carotid and cerebral arteries may contribute greatly to the maintenance of adequate cerebral perfusion during the initiation of antihypertensive treatment.16 ' 17 The buffering function of the large arteries has been discussed. Antihypertensive drugs, because of their direct action on the blood vessel wall through the influence on local vasoactive substances or on their receptors, may modify arterial compliance differentially. Recent investigations have shown that some 3-adrenergic antagonist blockers and hydralazine-like compounds29' 67 do not modify arterial compliance despite inducing a reduction in blood pressure. Shortand long-term administration of captopril and enalapril to patients with essential hypertension produce an increase in arterial compliance both in the systemic and brachial circulations.12 There are several possible mechanisms for this increased arterial compliance. First, the blockade of local angiotensin antagonizes its direct effect on the smooth muscle cell as well as its indirect effect via norepinephrine release. Second, the reduction in blood pressure itself may favor the enhancement of compliance. 4 Third, since the circumferential elasticity of a blood vessel is related to its radius rather than to the pressure itself,1-4 18 result of the blockade of local angiotensin production in arterial smooth muscle rather than the result of a reduction in the dynamic characteristics of the muscle load associated with stretch, since the usual negative correlation observed between pressure and distensibility disappeared after converting-enzyme inhibition. Thus, converting-enzyme inhibition augments the buffering function of large arteries. This unique effect may be important in reducing vascular injury, which may initiate the atherosclerotic processes.
Let us now examine the influence of antihypertensive treatment on afterload and cardiac hypertrophy. It has been suggested that antiadrenergic agents such as methyldopa or propanolol facilitate regression of cardiac hypertrophy, whereas nonspecific vasodilators such as hydralazine do not.8 Secondary activation of the sympathetic nervous system has been suggested to explain the lack of effect of hydralazine. In a recent study, captopril and cadralazine were studied in patients with essential hyp-ertension.28 37 Cadralazine did not modify arterial distensibility despite a reduction in blood pressure. This was probably due to reflex activation of the sympathetic nervous system. In contrast, captopril markedly increased volume distensibility at the same level of blood pressure reduction obtained with cadralazine. Furthermore, while systolic pressure decreased to a similar extent after the two drugs, heart rate increased significantly only with cadralazine. Therefore, it can be concluded that systolic pressure-heart rate product increases with cadralazine and decreases with captopril. This reduction in systolic pressure-heart rate product with captopril suggests a less pronounced end-systolic stress per unit time after converting-enzyme inhibition. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The effect of vasodilator agents on end-systolic wall stress is extremely important in severe congestive heart failure. Converting-enzyme inhibitors reduce arterial impedance and have been shown to be efficacious in the treatment of dilated congestive cardiomyopathy. 31' 32 Recently, therapy with converting-enzyme inhibitors has been shown to improve the survival of patients with congestive heart failure.69' 70 Monotherapy with hydralazine has been proven to be of limited value.71
On the other hand, the recent results of the Veterans Administration heart failure study showed that hydralazine in combination with isosorbide dinitrate was effective in improving subjective and objective performance as well as the survival of patients with heart failure.72 Since nitrates increase arterial compliance by increasing arterial volume, it is likely that the addition of nitrates to hydralazine is the crucial factor responsible for the efficacy of this combination therapy.
In summary, large arteries play an important role in cardiovascular hemostasis through their conduit and buffering functions. These properties are influenced by various circulating and local vasoactive substances. The vascular renin-angiotensin system is emerging as an important autocrine or paracrine system that influences large and small vessel functions. In hypertensive subjects, there is experimental and clinical evidence to suggest that the reduced arterial compliance may, in part, be due to activation of the local renin-angiotensin system. Indeed, converting-enzyme inhibitors increase arterial caliber and distensibility, which may be important in promoting regression of cardiac hypertrophy, reducing hypertensive vascular injury, and preventing congestive heart failure.
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